At the annual ASCO meeting in June 2012, we presented data from our ALN-VSP Phase I extension study. Overall, the results demonstrated disease control lasting more than six months in the majority of patients treated on the extension study, including a complete response (CR) in an endometrial cancer patient who had multiple liver metastases.
View our poster (3.72 MB PDF) View our releasePosts Tagged with: Liver Cancers
January 1, 2012
ALN-VSP Historical Press Releases
For your convenience we have collected a list of historical releases that cover the historical progress of our clinical program for liver cancers*
2012
06/04/2012 Alnylam Presents Data from its Phase I Extension Study2011
04/06/2011 Alnylam Presents Phase I Data for ALN-VSP 18/05/2011 Alnylam Reports Positive Clinical Results for ALN-PCS 31/03/2011 Alnylam Completes Enrollment in ALN-VSP Phase I Clinical Trial2010
18/11/2010 Alnylam Presents Additional Interim Phase I Data for ALN-VSP 18/11/2009 Alnylam Presents New Pre-clinical Data on ALN-VSP 10/11/2010 Alnylam Presents Preliminary Phase I Data 29/10/2010 Alnylam Scientists to Present New Data on RNAi Therapeutics 07/06/2010 Alnylam Presents Preliminary Phase I Data 27/05/2010 Regulus Therapeutics Receives Exclusive License for Intellectual Property 20/05/2010 Alnylam’s ALN-VSP Abstract Published by American Society of Clinical Oncology2009
18/11/2009 Alnylam Presents New Pre-clinical Data 03/04/2009 Alnylam Initiates Phase I Clinical Study 23/01/2009 Alnylam Receives Clearance from FDA to Initiate Phase I Study2008
31/03/2008 Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy2007
17/04/2007 Alnylam Presents Data from its Phase I Extension StudyJuly 26, 2011
ALN-VSP Podcast Discussing Phase I Clinical Trial
In August 2011, we recorded a podcast around our ALN-VSP program for the treatment of liver cancers. The discussion was led by our own Jared Gollob, M.D., Senior Director of Clinical Research, and Dr. Geoffrey Shapiro, M.D., Ph.D. of the Dana Farber Cancer Institute.
Listen to podcast discussing ALN-VSP and future of Phase I oncology trials (37.6MB MP3) Read our press release ALN-VSP Ph1 ClinicalStudyResults-ASCO2011 (1.2MB PPT)June 29, 2011
ALN-VSP Data at 2011 ASCO Meeting
At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement.
Read our press release ALN-VSP PhI ClinicalStudyResults-ASCO2011 (1.2MB PPT) ALN-VSP RNAi Roundtable, May 2011 (2.2 MB PPT) Listen to Dr. Jared Gollob discuss ALN-VSP data at ASCO 2011 (3.1MB MP3)May 31, 2011
Alnylam RNAi Roundtable: ALN-VSP Proof of Mechanism Data
In May 2011, we held a roundtable discussion focused on our ALN-VSP program; specifically, the important proof of mechanism data that we had reported on earlier in the year.
ALN-VSP RNAi Roundtable webcast, May 2011 (65 MB MP3) ALN-VSP RNAi Roundtable, May 2011 (2.2 MB PPT) Read our press releaseJanuary 4, 2011
RNAi in Man: Initial Results from ALN-VSP Phase I Clinical Trial
In January 2011, Jared Gollob, M.D., Senior Director of Clinical Research at Alnylam, presented important clinical data from our ALN-VSP Phase I trial, demonstrating that RNAi can be harnessed in man using systemically delivered RNAi therapeutics.
Read our press release Dana Farber ALN-VSP Proof of Mechanism